Blinatumomab induces remission in relapsed or chemorefractory BCP-ALL (also in Philadelphia-positive leukemia) [4,5,15,16], but it is associated with CD19 antigen modulation [1,14,17]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.